drugset / Trial / NCT00359177

Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

NCT00359177

Phase 1 Completed 24 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate how subjects with mild or moderate liver problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.

Timeline

Start
2005-12-01
Primary completion
2006-10-12
Completion
2006-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule 100 mg Oral

Indications

No indication recorded.